Observational Evaluation of Atopic Dermatitis in Pediatric Patients

Investigation of Characteristics and Treatment Patterns in Pediatric Atopic Dermatitis

Recruiting
11 years or below
All
Phase N/A
1856 participants needed
43 Locations

Study Overview

Primary Objectives:

  • To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.
  • To evaluate the time-course of AD and selected atopic comorbidities.

Secondary Objectives:

  • To characterize disease burden and unmet need.
  • To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching).
  • To document the real-world effectiveness and safety of treatments.

Study Details

The study duration is 60 months.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Dermatitis Atopic
  • Age: 11 years or below
  • Gender: All

Inclusion criteria:

  • Patients with moderate to severe AD, according to the Investigator's assessment;
  • Currently receiving systemic treatment (including phototherapy) for atopic dermatitis or currently on topical treatment, but otherwise candidates for systemic treatment.

Exclusion criteria:

  • Concurrent participation in an interventional clinical trial which modifies patient care.
        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.

Updated on 15 Dec 2023. Study ID: NCT03687359

This study investigates pediatric patients with moderate to severe atopic dermatitis (AD). Atopic dermatitis is a chronic skin condition that causes itchy, inflamed skin. The purpose of this study is to describe the characteristics of these patients whose condition is not well controlled by topical treatments or when such treatments are not suitable. The study also aims to evaluate the progression of AD and related conditions over time.

The study will involve examining the burden of the disease and the unmet needs of patients. Participants' real-world treatment patterns, including dosing and duration, will be documented. The study will also look at the effectiveness and safety of current treatments in real-world settings.

  • Who can participate: Children with moderate to severe atopic dermatitis who are currently receiving systemic treatment or are candidates for it can participate. Patients must not be part of another clinical trial that changes their care.
  • Study details: Participants will be observed to understand their treatment patterns and the burden of their disease. The study will document the effectiveness and safety of treatments being used in real-world settings.
  • Study Timelines: The study will last 60 months.

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language